Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial
Assuntina G. Sacco, Ruifeng Chen, Francis P. Worden, Deborah Jean Lee Wong, Douglas R. Adkins, Paul Swiecicki, Wanxing Chai‐Ho, Peter Oppelt, Debanjali Ghosh, Julie Bykowski, Alfredo Molinolo, Emily Pittman, Mónica V. Estrada, Kathryn A. Gold, Gregory A. Daniels, Scott M. Lippman, Amanda Natsuhara, Karen Messer, Ezra E.W. Cohen
Topics & Concepts
CetuximabMedicinePembrolizumabResponse Evaluation Criteria in Solid TumorsOncologyInternal medicineHead and neck squamous-cell carcinomaClinical endpointPopulationPhases of clinical researchHead and neck cancerImmunotherapyClinical trialCancerColorectal cancerEnvironmental healthHead and Neck Cancer StudiesCancer Immunotherapy and BiomarkersEsophageal Cancer Research and Treatment